Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
Highest Quality | For Research Use Only

B7-33

Buy B7-33 Peptide Czech Republic

B7-33 peptide, or B-type Natriuretic Peptide (BNP) 7-33, is a truncated form of the B-type natriuretic peptide. This peptide has been a subject of significant interest in the field of cardiovascular research due to its cardio-protective properties. One of the most notable benefits of B7-33 is its ability to reduce myocardial infarct size. In addition to its cardioprotective effects, B7-33 also exhibits anti-fibrotic properties. It has been demonstrated to inhibit cardiac fibrosis, thereby improving cardiac function and potentially delaying the progression of heart failure.

Showing all 3 results

Potential Benefits of B7-33 Peptide

  • Cardiac Remodeling Attenuation: B7-33, a relaxin family peptide receptor 1 agonist, has been shown in studies to attenuate adverse cardiac remodeling associated with myocardial infarction (MI) in mice [1].
  • Functionally Selective Agonist of RXFP1: B7-33 is a functionally selective agonist of the G protein-coupled receptor, RXFP1. This functional selectivity could enhance the therapeutic potential of the peptide [2].
  • Stability Enhancement: B7-33 has been developed to have a higher affinity for its target, potentially providing stability and enhancing its therapeutic benefits [3].
  • Cardioprotective Effects: Research suggests the peptide maintains the cardioprotective effects of relaxin and has been shown to reduce left ventricular fibrosis more rapidly than other treatments [4].
  • Analgesic Effect: According to research, B7-33 has demonstrated an analgesic effect on persistent inflammatory pain in mice, offering potential benefits in pain management [5].
  • Antifibrotic Properties: Studies indicate B7-33 has been found to efficiently prevent or reverse organ fibrosis and dysfunction in rodent models of heart or lung disease, highlighting its potential as an anti-fibrotic agent [5].
  • Long-Acting Single-Chain Peptide Mimetic: B7-33 is a potent and long-acting single-chain peptide mimetic of human relaxin-2, which research suggests could be beneficial for cardiovascular diseases [6].
  • Potential Therapeutic Applications in Fibrosis: B7-33 was administered to mouse models with unilateral ureteral obstruction (UUO), and it showed promising results in managing fibrosis, which could expand its therapeutic applications [7].

References

[1] https://pubmed.ncbi.nlm.nih.gov/32295457/

[2] https://pubmed.ncbi.nlm.nih.gov/30155023/

[3] https://www.mdpi.com/ 1422-0067/24/16/12670

[4] https://www.sciencedirect.com/science/ article/pii/S0753332223001580

[5] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC8213244/

[6] https://pubmed.ncbi.nlm.nih.gov/33555858/

[7] https://www.mdpi.com/ 2218-273X/13/8/1179

 

ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://czech-republic.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.